VNDA Vanda Pharmaceuticals Inc.companySEC Filings & Insider Trading Activity 2026
Latest Vanda Pharmaceuticals Inc. (VNDA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 12, 2026, a 10-Q quarterly report filed on October 30, 2025, an 8-K current report filed on April 22, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Vanda Pharmaceuticals Inc. (VNDA) (SEC CIK 1347178), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Vanda Pharmaceuticals filed a Reg FD disclosure (Item 7.01), signaling a potentially market-moving communication to investors
- • No substantive disclosure content included in this section — material information likely contained in an accompanying exhibit
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Vanda Pharmaceuticals Inc. (VNDA) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 22, 2026 | — | — | — |
8-K | Apr 2, 2026 | — | — | — |
8-K | Mar 10, 2026 | — | Analysis | — |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Feb 19, 2026 | — | — | |
10-K | Feb 12, 2026 | Dec 31, 2025 | — | |
8-K | Feb 11, 2026 | — | — | |
8-K | Jan 8, 2026 | — | — | |
8-K | Dec 31, 2025 | — | — | |
8-K | Dec 4, 2025 | — | — | |
8-K | Nov 28, 2025 | — | — | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | — | |
10-Q | Jul 31, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 14, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 8, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 28, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Feb 9, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — |
Frequently Asked Questions
What are the latest VNDA SEC filings in 2026?
Vanda Pharmaceuticals Inc. (VNDA) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did VNDA file its most recent 10-K annual report?
Vanda Pharmaceuticals Inc. (VNDA) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view VNDA 10-Q quarterly reports?
Vanda Pharmaceuticals Inc. (VNDA)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every VNDA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has VNDA filed recently?
Vanda Pharmaceuticals Inc. (VNDA)'s most recent 8-K was filed on April 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find VNDA insider trading activity (Form 4)?
SignalX aggregates every VNDA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does VNDA file with the SEC?
Vanda Pharmaceuticals Inc. (VNDA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VNDA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vanda Pharmaceuticals Inc. (VNDA).
What is VNDA's SEC CIK number?
Vanda Pharmaceuticals Inc. (VNDA)'s SEC CIK (Central Index Key) number is 1347178. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1347178 to look up all VNDA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find VNDA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Vanda Pharmaceuticals Inc. (VNDA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Vanda Pharmaceuticals Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 78+ filings.